ENZC.US Enzolytics Inc

Healthcare Biotechnology USA Stocks
0.0005 USD
Close of Nov 12, 2026
0.0002 0.0013
Market cap
USD 2.42M
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is ENZC.US undervalued?

Graham number

The Graham number of Enzolytics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Enzolytics Inc fundamental analysis

No fundamental analysis for Enzolytics Inc yet.

Enzolytics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Enzolytics Inc

Enzolytics, Inc. a drug development company, focuses on the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. It's patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The company has clinically tested anti-HIV therapeutics. In addition, the company's proprietary cell line produces human monoclonal an…

Full company profile